BUY $ATXS
• Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, announced that it will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5th in New York, New York.
• The company is a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases.
• The company has announced that it will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5th in New York.
BOSTON / Aug 29, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5th in New York, New York.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.
BUY $ATXS
| Last Trade: | US$11.61 |
| Daily Change: | 0.11 0.96 |
| Daily Volume: | 268,369 |
| Market Cap: | US$655.150M |
August 30, 2024 August 12, 2024 August 12, 2024 August 07, 2024 | |
BUY $ATXS
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE